TY - JOUR
T1 - Preliminary clinical evaluation of free/total PSA ratio by the IMMULITE® system
AU - Correale, M.
AU - Pagliarulo, A.
AU - Donatuti, G.
AU - Sturdà, F.
AU - Capobianco, A. M L
AU - Stigliani, V.
AU - Rizzello, M.
AU - Circhietta, S.
AU - Pignatelli, F.
AU - Leone, L.
AU - Frusciante, V.
AU - Modoni, S.
AU - Schittulli, F.
PY - 1996/1
Y1 - 1996/1
N2 - The role of free (F) and complexed serum PSA is now under investigation. In the present study, we evaluated the clinical significance of F-PSA and F/Total (T) PSA ratio in a preliminary series of samples from 88 patients with prostate cancer (PC), 113 with benign prostatic disease (BPD); and 98 with non-prostatic disease (NP). We used the F-PSA and third generation T-PSA (DPC, Los Angeles, USA) chemiluminescent enzyme immunometric assays with the IMMULITE automated system. At the 10 ng/ml cutoff for T-PSA levels, we obtained a sensitivity of 83% with a specificity of 100% in NP and 80% in BPD. The addition of the F/T ratio - rather than F-PSA levels - was useful to better discriminate PC and BPD in the cases erroneously classified by T-PSA alone: 44/68 samples (65%) were correctly diagnosed. Moreover, the F/T ratio was particularly effective in the critical T-PSA range between 4.1-9.9 ng/ml; 26/40 cases (65%) were correctly evaluated. In conclusion, the F/T ratio seems to be an interesting auxiliary test to T-PSA, to be reserved for selected cases where additional diagnostic information is necessary.
AB - The role of free (F) and complexed serum PSA is now under investigation. In the present study, we evaluated the clinical significance of F-PSA and F/Total (T) PSA ratio in a preliminary series of samples from 88 patients with prostate cancer (PC), 113 with benign prostatic disease (BPD); and 98 with non-prostatic disease (NP). We used the F-PSA and third generation T-PSA (DPC, Los Angeles, USA) chemiluminescent enzyme immunometric assays with the IMMULITE automated system. At the 10 ng/ml cutoff for T-PSA levels, we obtained a sensitivity of 83% with a specificity of 100% in NP and 80% in BPD. The addition of the F/T ratio - rather than F-PSA levels - was useful to better discriminate PC and BPD in the cases erroneously classified by T-PSA alone: 44/68 samples (65%) were correctly diagnosed. Moreover, the F/T ratio was particularly effective in the critical T-PSA range between 4.1-9.9 ng/ml; 26/40 cases (65%) were correctly evaluated. In conclusion, the F/T ratio seems to be an interesting auxiliary test to T-PSA, to be reserved for selected cases where additional diagnostic information is necessary.
KW - Benign prostatic hypertrophy
KW - Free-PSA
KW - Prostate cancer
KW - PSA ratio
UR - http://www.scopus.com/inward/record.url?scp=15844409069&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=15844409069&partnerID=8YFLogxK
M3 - Article
C2 - 8740638
AN - SCOPUS:15844409069
VL - 11
SP - 24
EP - 28
JO - International Journal of Biological Markers
JF - International Journal of Biological Markers
SN - 0393-6155
IS - 1
ER -